Close Menu

NEW YORK (360Dx) – A diagnostic test used by Mayo Clinic to detect a rare neurological disease involves standard techniques and is not subject to patent law, a federal appeals court ruled Wednesday.

The appellate court's decision to uphold a district court ruling in the patent dispute effectively denied claims by Quest Diagnostics' Athena Diagnostics division that it was owed royalties for the testing. The US Court of Appeals for the Federal Circuit sided with Mayo in a 2-1 decision.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
21
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

May
22

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.